Effects of ivabradine on heart rate and left ventricular function in healthy cats and cats with hypertrophic cardiomyopathy

Sabine C. Riesen Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210.

Search for other papers by Sabine C. Riesen in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Karsten E. Schober Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210.

Search for other papers by Karsten E. Schober in
Current site
Google Scholar
PubMed
Close
 DVM, Dr med vet, Dr habil
,
Danielle N. Smith Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210.

Search for other papers by Danielle N. Smith in
Current site
Google Scholar
PubMed
Close
 DVM
,
Cristiane C. Otoni Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210.

Search for other papers by Cristiane C. Otoni in
Current site
Google Scholar
PubMed
Close
 DVM
,
Xiaobai Li Department of Biostatistics, College of Public Health, The Ohio State University, Columbus, OH 43210.

Search for other papers by Xiaobai Li in
Current site
Google Scholar
PubMed
Close
 PhD
, and
John D. Bonagura Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210.

Search for other papers by John D. Bonagura in
Current site
Google Scholar
PubMed
Close
 DVM, MS
Restricted access
Purchase Article

Abstract

Objective—To evaluate the effects of the pacemaker funny current (If) inhibitor ivabradine on heart rate (HR), left ventricular (LV) systolic and diastolic function, and left atrial performance in healthy cats and cats with hypertrophic cardiomyopathy (HCM).

Animals—6 healthy cats and 6 cats with subclinical HCM.

Procedures—Anesthetized cats underwent cardiac catheterization and were studied over a range of hemodynamic states induced by treatment with esmolol (200 to 400 μg/kg/min, IV), esmolol and dobutamine (5 μg/kg/min, IV), ivabradine (0.3 mg/kg, IV), and ivabradine and dobutamine. Left ventricular systolic and diastolic function, cardiac output, and left atrial function were studied via catheter-based methods and echocardiography.

Results—Treatment with ivabradine resulted in a significant reduction of HR, rate-pressure product, and LV contractile function and a significant increase in LV end-diastolic pressure, LV end-diastolic wall stress, and LV relaxation time constant (tau) in cats with HCM. Concurrent administration of ivabradine and dobutamine resulted in a significant increase of LV contractility and lusitropy, with blunted chronotropic effects of the catecholamine. Left atrial performance was not significantly altered by ivabradine in cats with HCM. Regression analysis revealed an association between maximum rate of LV pressure rise and tau in cats with HCM.

Conclusions and Clinical Relevance—Ivabradine had significant effects on several cardiovascular variables in anesthetized cats with HCM. Studies in awake cats with HCM are needed to clinically validate these findings.

All Time Past Year Past 30 Days
Abstract Views 177 0 0
Full Text Views 3089 2132 267
PDF Downloads 738 299 26
Advertisement